Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9390020 | 0.76 | MAPT (0.52) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL31406264 | 0.74 | GAA (0.50) | MAPTGAA | |
| SCHEMBL25290828 | 0.74 | GAA (0.50) | MAPTGAA | |
| SCHEMBL27328216 | 0.74 | MAPT (0.45) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL11719213 | 0.74 | GAA (0.45) | MAPTGAASMN1; SMN2P2RX4 | |
| SCHEMBL4770605 | 0.74 | MAPT (0.45) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Hydrochloric Acid SCHEMBL30563096 | 0.72 | GAA (0.48) | MAPTGAA | |
| SCHEMBL10345841 | 0.71 | MAPT (0.42) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL30890804 | 0.70 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL27383896 | 0.69 | GAA (0.45) | MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4192872-A | ANTI -PARKINSONISM ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4052506-A | BENZAZEPINES | SMITHKLINE CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4011319-A | STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS | SMITHKLINE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |